Format

Send to

Choose Destination
Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.

Author information

1
Department of Medicine, Imperial College London, London, UK.
2
Leiden University Medical Centre, Leiden, The Netherlands.
3
Medizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.
4
Institut Paoli Calmette, Marseille, France.
5
The Royal Marsden Hospital, London, UK.
6
Centre Hospitalier Universitaire, Nantes, France.
7
Centre Hospitalier Universitaire, Toulouse, France.
8
Centre Hospitalier Universitaire, Bordeaux, France.
9
Nottingham City Hospital, Nottingham, UK.
10
Sahlgrenska University Hospital, Göteborg, Sweden.
11
St James's Institute of Oncology, Leeds, UK.
12
Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands.
13
Department of Haematology, Hopital Saint-Antoine, Paris, France.
14
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

Abstract

Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged <65 years. To understand age-related trends in utilisation and outcome of AHCT, we analysed 53 675 MM patients who underwent a first AHCT in 31 European countries between 1991 and 2010. The number of patients undergoing AHCT increased for all age groups (<40, 40-49, 50-59, 60-64, 65-69 and ⩾70 years) throughout the observation period. The highest increase was observed for patients aged ⩾65 years, who accounted for 3% of AHCTs in 1991-1995 and for 18.8% of AHCTs in 2006-2010. Risk factors associated with survival over the entire observation period (P<0.001) were calendar period, remission status at AHCT, gender, disease duration before AHCT and age. Survival improved considerably more in older than in younger patients in recent years. In 2006-2010, median 2- and 5-year post-transplant survival ranged from 85.9 and 61.5% in patients <40 years to 80.2 and 49.7% in those ⩾70 years. All-cause day-100 mortality decreased throughout the observation period to ⩽2.4% for all age groups in 2006-2010. The results of this study demonstrate increased utilisation and safety of AHCT with improved post-transplant survival particularly in elderly MM patients in recent years in Europe.

PMID:
25387088
DOI:
10.1038/bmt.2014.255
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center